For those of you that know me will be aware that I am an advocate of Kratom (for medicinal use). The FDA decided (for the third time) to make the drug illegal - much as they have done with other substances, only to then bring out their own allopathic alternative with a different name.
It has finally been given the seal of approval by the World Health Organisation in that there is insufficient evidence to consider Kratom to be an unsafe drug. Needless to say, the WHO recommendation has put a stop to the FDA trying to prevent Kratom reliving pain and suffering for so many people - myself included. This is a good day for us all.
I accept all views from members on this drug, but this has been posted to show that after a significant amount of research by the WHO, Kratom is not considered to be any more unsafe that those allopathics drugs currently available through the medical community, but will remain under surveillance.
Source can be found here; https://cdn.who.int/...vrsn=9c380ac2_5
Kratom, mitragynine, 7-hydroxymitragynine
Substance identification
Kratom is the common term for Mitragyna speciosa, a tree native to Southeast Asia. Kratom use is almost exclusively oral, typically by chewing the leaves, ingesting powdered leaf, or drinking a kratom infusion or decoction, or by ingesting powdered leaf as a capsule or pill or dissolved in a beverage. Other forms such as extracts and resins are also used.
Several alkaloids have been detected in kratom plants. The main known psychoactive components of kratom are mitragynine and 7-hydroxymitragynine, both of which are found in the leaves of Mitragyna speciosa. Mitragynine is the most abundant alkaloid in kratom. Whilst 7-hydroxymitragynine is a minor alkaloid, it is also a metabolite of mitragynine.
WHO review history
Kratom has been under ECDD surveillance since 2020 due to a country level report indicating the potential for abuse, dependence, and harm to public health from mitragynine and 7-hydroxymitragynine, and a report from an international organization regarding documented fatalities associated with kratom Annex I. 44th WHO ECDD Summary assessments, findings and recommendations 11-15 October 2021 8 use. A pre-review on kratom, mitragynine, and 7-hydroxymitragynine was initiated following consideration of these reports.
Similarity to known substances and effects on central nervous system
Mitragynine and 7-hydroxymitragynine are partial agonists at the mu-opioid receptor. Human studies demonstrate the analgesic effects of kratom, while kratom extract, mitragynine and 7- hydroxymitragynine have been shown to be antinociceptive in animal models. The antinociceptive effects are reversed by an opioid antagonist.
Mitragynine also binds to adrenergic receptors, serotonergic and dopamine receptors. Although there is limited information regarding its effects at these receptors, kratom extracts and mitragynine have been reported in animal studies to have a variety of non-opioid-like behavioural effects, including antidepressant and antipsychotic effects.
Reported adverse effects as a result of kratom intoxication have included neuropsychiatric (agitation, confusion, sedation, hallucinations, tremor, seizure, coma), cardiovascular (tachycardia, hypertension), gastrointestinal (abdominal pain, nausea, vomiting) and respiratory (respiratory depression) symptoms. A number of cases of kratom-associated liver toxicity have been documented.
Dependence potential
In animal models, repeated dosing with mitragynine produced dependence, evidenced by naloxoneprecipitated withdrawal. The withdrawal syndrome from kratom appears to be less severe than withdrawal from morphine. In humans, opioid-like withdrawal symptoms have been reported following cessation of kratom use. Limited epidemiological evidence indicates that withdrawal is usually mild. There are a small number of cases of neonatal opioid withdrawal symptoms in neonates born to mothers who used kratom regularly.
Actual abuse and/or evidence of likelihood of abuse
Animal studies with kratom extracts have not shown abuse liability in one animal model. Mitragynine and 7-hydroxymitragynine have effects indicative of abuse liability in some animal models but not in others. Mitragynine is not self-administered by animals, while 7-hydroxymitragynine has been shown to be self administered, supporting a likely abuse liability.
Kratom can produce serious toxicity in people who use high-doses, but the number of cases is probably low as a proportion of the total number of people who use kratom. Although mitragynine has been analytically confirmed in a number of deaths, almost all involve use of other substances, so the degree to which kratom use has been a contributory factor to fatalities is unclear.
Kratom and mitragynine have been associated with cases of driving under the influence, but their role in driving impairment could not be established in most instances.
Multiple countries across various regions report nonmedical use of kratom. Seizures of kratom and related products have been reported in several countries.
Annex I. 44th WHO ECDD Summary assessments, findings and recommendations 11-15 October 2021 9
Therapeutic usefulness
People report using kratom to self-medicate a variety of disorders and conditions, including pain, opioid withdrawal, opioid use disorder, anxiety and depression. Kratom is being used as a part of traditional medicine in some countries.
Research is ongoing to determine the basic pharmacology and the potential therapeutic value of kratom, mitragynine and 7-hydroxymitragynine.
Recommendation
Kratom contains multiple alkaloids. The two main known psychoactive alkaloids, mitragynine and 7- hydroxymitragynine, produce at least some effects similar to opioids under international control. Mitragynine, the most abundant of these alkaloids, also has non-opioid actions, the significance of which is unclear. There is mixed evidence on the abuse liability of mitragynine in animal models. Kratom is used for self-medication for a variety of disorders but there is limited evidence of abuse liability in humans. Cessation of regular use of kratom may lead to withdrawal symptoms.
The Committee considered information regarding the traditional use and investigation into possible medical applications of kratom.
The Committee concluded that there is insufficient evidence to recommend a critical review of kratom. With respect to mitragynine and 7-hydroxymitragynine, the Committee, except for one member, also concluded that there is insufficient evidence to recommend a critical review at this time. Recommendation: The Committee recommended that kratom, mitragynine and 7-hydroxymitragynine be kept under surveillance by the WHO Secretariat.
